Full-Time

Account Manager

Sartorius

Sartorius

5,001-10,000 employees

Laboratory instruments and bioprocess solutions

No salary listed

Delhi, India

In Person

Master's

Category
Sales & Account Management (1)
Required Skills
Microsoft Office
Sales
Lead Generation
CRM
Marketing

Get referred to Sartorius

See people who can refer or advise you

Requirements
  • A Master's degree in life sciences or engineering in Biotechnology or Chemical Engineering is required.
  • A minimum of 8-10 years of field sales experience is required, preferably with laboratory or process-based experience in Life Science.
  • Hands-on knowledge and proactive usage of SFDC and other customer relationship management tools are required.
  • Excellent communication in English and sales negotiation skills are required.
  • The candidate must be self-motivated, energetic, results-oriented, able to work independently, and demonstrate a strong sense of responsibility.
  • Good teamwork skills and the proven ability to work with cross-functional teams are required.
  • Willingness and ability to travel frequently are required.
  • Proven software skills, such as Microsoft Office, are required.
Responsibilities
  • Promote the organization's products and services within an assigned geographic area, product range, or key account to achieve sales and revenue targets.
  • Identify new business opportunities aligned with the organization's overall market and growth strategy.
  • Actively use SFDC to manage and document leads, opportunities, customer interactions, and sales activities, ensuring that customer and opportunity information is current and accurate in the CRM system.
  • Analyze SFDC data for assigned customers to identify trends, generate customer insights, and track sales performance.
  • Drive newly launched innovative products and services into the marketplace and proactively follow up on successful implementation of sales activity.
  • Assess and analyze customer needs, generate leads, respond to customer inquiries, and suggest appropriate products and services.
  • Develop and implement account plans and request and coordinate resources in line with the account plans.
  • Work closely with cross-functional teams to create higher market perception and successful strategies to gain business from an account.
  • Coordinate and participate in marketing activities in the assigned territory.
  • Frequently assess the potential of each customer and plan to realize it as business.
  • Manage and build strong customer relationships for long-term partnership.
Desired Qualifications
  • Higher level of education would be beneficial.
  • Preferable laboratory or process-based experience in Life Science.

Sartorius is a global partner in life sciences research and biopharmaceutical manufacturing. It provides laboratories with innovative instruments and consumables for research and quality control, and it offers Bioprocess Solutions focused on single-use systems that help manufacture biotech medicines, vaccines, and cell- and gene- therapies safely, quickly, and cost-effectively. Its products support the full path from drug discovery to commercial manufacturing, with a large worldwide footprint of more than 60 sites and a mission to help more people access better medicines. Sartorius differentiates itself through its broad portfolio spanning lab and bioprocess needs, a strong emphasis on single-use technologies, continuous portfolio expansion via acquisitions, and deep expertise serving pharmaceutical, biotech, and academic customers. Its goal is to simplify progress from research and development to scalable manufacturing so that life-saving medicines can reach patients worldwide.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Göttingen, Germany

Founded

1870

Get referred to Sartorius

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • H1 2026 sales grew 7.7% operationally; underlying EBITDA margin reached 30.3%.
  • Management confirmed 2026 guidance after Q1 2026 and H1 2026 results.
  • Employee count rose to 14,279 by June 30, 2026, signaling active hiring.

What critics are saying

  • Reuters on July 23, 2026 said growth lands in the lower half.
  • U.S. tariff refunds forced customer reimbursements, hitting 2026 revenue and margins.
  • Gator Bio beat Sartorius in 2026 U.S. patent rulings, weakening bioanalytical defensibility.

What makes Sartorius unique

  • Sartorius monetizes recurring bioprocess consumables, not just lumpy capital equipment.
  • Ann Arbor’s $100 million bioanalytics center deepens U.S. service and application support.
  • SIMCA and SIMCA-online embed Sartorius into process monitoring workflows at biopharma plants.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Flexible Work Hours

Wellness Program

Professional Development Budget

Company News

Yahoo Finance
Jul 23rd, 2026
Sartorius reports 7.7% sales growth as bioprocess equipment stabilises

Sartorius reported solid first-half results, with constant-currency sales up 7.7% and underlying EBITDA rising 3.9% as margins improved to 30.3%. Management confirmed full-year guidance. Bioprocess Solutions led performance, growing 8.3% in constant currencies. Consumables drove growth, whilst equipment stabilised slightly. Chief executive Michael Grosse said demand for biologics remains robust, particularly in monoclonal antibody manufacturing. However, advanced-therapy orders from two customers were delayed and could shift revenue into 2027. Tariff refunds and accounting effects distorted reported results but did not change underlying business trends. The company booked €26 million in customer compensation related to tariffs. Operating cash flow and free cash flow both improved sharply in the first half.

AD HOC NEWS
May 15th, 2026
Sartorius completes full takeover of Stedim Biotech, delisting bioprocessing unit from Euronext Paris

Sartorius Stedim Biotech is set to be delisted from Euronext Paris following a squeeze-out by majority shareholder Sartorius Group. The voluntary tender offer and subsequent acquisition process, which began in early 2024, will transition the company from a separately traded stock into a fully integrated part of Sartorius Group. Headquartered in Aubagne, France, Sartorius Stedim Biotech develops bioprocessing equipment and single-use technologies for biopharmaceutical manufacturing. Its products include bioreactors, filtration systems and process automation tools used by pharmaceutical and biotech companies globally. North America represents a key market, with many US-based biopharma firms using its technologies. The company experienced normalised growth following pandemic-era demand surges, with customers working through elevated inventories accumulated during vaccine production. Despite short-term headwinds, long-term demand drivers remain supported by expanding biologics and advanced therapy pipelines.

wallstreet:online AG
May 6th, 2026
Sartorius completes $560M bond placement with 3.75% coupon to refinance existing debt

Sartorius has completed a €500 million bond placement via its Dutch subsidiary Sartorius Finance B.V. The five-year bond, targeted at institutional investors, was more than four times oversubscribed and carries a 3.75% annual coupon. The life science group will use the proceeds for general corporate purposes, including refinancing existing debt. This includes the redemption of a €650 million bond with a 4.25% interest rate due in autumn 2026. Sartorius has applied for admission to trading on the Euro MTF market of the Luxembourg Stock Exchange. Chief financial officer Florian Funck said the successful issuance strengthens the company's balanced debt maturity profile and long-term financing position, whilst demonstrating investor confidence in Sartorius' strategic direction.

Sartorius
May 6th, 2026
Sartorius completes placement of bond with a volume of 500 million euros

May 6, 2026 – Sartorius has successfully issued a bond with a volume of 500 million euros via its Dutch subsidiary Sartorius Finance B.V.. The issue was targeted at institutional investors and met with strong demand, being more than 4 times oversubscribed.

Associated Press
Mar 16th, 2026
Sartorius launches platform to cut CAR-T manufacturing costs by 90% and quadruple output

Sartorius has launched the Eveo Cell Therapy Platform, an integrated system for producing autologous cell therapies including CAR-T treatments. The modular platform can increase output up to fourfold in existing cleanroom space whilst reducing manufacturing costs by approximately 90 percent. The system integrates cell selection, activation, gene modification, expansion and final formulation into a closed system. Its compact design allows a single operator to process eight patient batches simultaneously in the space traditionally needed for two, potentially producing over 350 doses annually compared to today's 100 doses in the same footprint. A successful pilot with CDMO ElevateBio validated the platform's real-world applicability. Sartorius will begin taking orders in September 2026, with first deliveries expected in 2027.